110 related articles for article (PubMed ID: 1927298)
1. Neither exogenous nor endogenous GnRH stimulation alters the bio/immuno ratio of serum LH in healthy women and in polycystic ovarian disease.
Ding YQ; Anttila L; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
Acta Obstet Gynecol Scand; 1991; 70(3):211-7. PubMed ID: 1927298
[TBL] [Abstract][Full Text] [Related]
2. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
4. Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with the high bio/immune ratio of LH in healthy women and in women with polycystic ovarian disease.
Ding YQ; Huhtaniemi I
Hum Reprod; 1991 Mar; 6(3):346-50. PubMed ID: 1955538
[TBL] [Abstract][Full Text] [Related]
5. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
Lubin V; Charbonnel B; Bouchard P
Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
[TBL] [Abstract][Full Text] [Related]
6. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
8. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
Waldstreicher J; Santoro NF; Hall JE; Filicori M; Crowley WF
J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
[TBL] [Abstract][Full Text] [Related]
9. LH measurements by in vitro bioassay and a highly sensitive immunofluorometric assay improve the distinction between boys with constitutional delay of puberty and hypogonadotropic hypogonadism.
Haavisto AM; Dunkel L; Pettersson K; Huhtaniemi I
Pediatr Res; 1990 Mar; 27(3):211-4. PubMed ID: 2181393
[TBL] [Abstract][Full Text] [Related]
10. Effects of luteinizing hormone releasing hormone (LHRH) upon bioactive and immunoreactive serum LH levels in normal subjects.
Dufau ML; Beitins IZ; McArthur JW; Catt KJ
J Clin Endocrinol Metab; 1976 Sep; 43(3):658-67. PubMed ID: 783183
[TBL] [Abstract][Full Text] [Related]
11. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
12. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
Rossmanith WG; Wirth U; Benz R; Wolf AS
Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
[TBL] [Abstract][Full Text] [Related]
13. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea.
Burger CW; Korsen T; van Kessel H; van Dop PA; Caron FJ; Schoemaker J
J Clin Endocrinol Metab; 1985 Dec; 61(6):1126-32. PubMed ID: 3932449
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins.
Apter D; Bützow TL; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1993 Apr; 76(4):940-9. PubMed ID: 8473410
[TBL] [Abstract][Full Text] [Related]
15. Naloxone increases bioactive LH in man: evidence for selective release of early LH pool.
Fraioli F; Fabbri A; Gnessi L; Moretti C; Bonifacio V; Isidori A; Dufau M
J Endocrinol Invest; 1985 Dec; 8(6):513-7. PubMed ID: 3914504
[TBL] [Abstract][Full Text] [Related]
16. The control of bioactive luteinizing hormone secretion in women with polycystic ovary syndrome.
Lobo RA; Shoupe D; Chang SP; Campeau J
Am J Obstet Gynecol; 1984 Feb; 148(4):423-8. PubMed ID: 6364811
[TBL] [Abstract][Full Text] [Related]
17. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays.
Imse V; Holzapfel G; Hinney B; Kuhn W; Wuttke W
J Clin Endocrinol Metab; 1992 May; 74(5):1053-61. PubMed ID: 1569153
[TBL] [Abstract][Full Text] [Related]
18. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
[TBL] [Abstract][Full Text] [Related]
19. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
20. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
Barletta C; Vagiri D; Scavo D
Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
